New England Research & Management lowered its stake in shares of Lannett Company, Inc. (NYSE:LCI) by 33.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The hedge fund owned 7,565 shares of the company’s stock after selling 3,875 shares during the period. New England Research & Management’s holdings in Lannett Company were worth $304,000 as of its most recent SEC filing.

Lannett Company, Inc. (NYSE:LCI) traded up 5.20% on Friday, hitting $36.40. The stock had a trading volume of 739,510 shares. The company’s 50 day moving average is $38.16 and its 200-day moving average is $46.50. Lannett Company, Inc. has a 12 month low of $31.81 and a 12 month high of $72.44. The stock has a market cap of $1.33 billion and a P/E ratio of 9.13.

Lannett Company (NYSE:LCI) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.10. The company had revenue of $106.40 million for the quarter, compared to analysts’ expectations of $103.90 million. The company’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.94 earnings per share. Analysts forecast that Lannett Company, Inc. will post $4.03 EPS for the current year.

Several research firms recently commented on LCI. Zacks Investment Research downgraded Lannett Company from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Craig Hallum cut Lannett Company from a “buy” rating to a “hold” rating in a research report on Thursday, November 5th. Susquehanna raised their target price on Lannett Company from $48.00 to $50.00 and gave the stock a “positive” rating in a research report on Tuesday, December 22nd. Finally, Oppenheimer reissued a “hold” rating on shares of Lannett Company in a research report on Tuesday, December 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $61.30.

Lannett Company, Inc. develops, manufactures, packages, markets and distributes solid oral (NYSE:LCI), extended release, topical and oral solution finished dosage forms of drugs. The Company also manufactures active pharmaceutical ingredients through its Cody Laboratories, Inc. (Cody Labs) subsidiary. The Company operates pharmaceutical manufacturing plants in Philadelphia, Pennsylvania and Cody, Wyoming. Customers of the Company’s pharmaceutical products include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, Governmental entities and health maintenance organizations. The Company’s products include Levothyroxine Sodium tablets, Digoxin tablets, Butalbital, Cocaine Topical Solution and Morphine Sulfate Oral Solution.

12 Month Chart for NYSE:LCI

Receive News & Ratings for Lannett Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.